{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-028186","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.274313+00:00","generated_at":"2026-05-16T06:30:50.338390+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Definium Therapeutics appoints Roger Adsett to board, expanding to 7 directors","bullets":["Board increased from 6 to 7 directors; Adsett appointed effective Jan 29, 2026.","Adsett receives $40,000 annual cash retainer paid quarterly in arrears.","Granted option for 50,000 common shares; vests 1/3 on first anniversary, then monthly.","Not assigned to any board committees initially."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-028186","json":"https://secwatch.observer/filing/0001193125-26-028186.json","markdown":"https://secwatch.observer/filing/0001193125-26-028186.md","text":"https://secwatch.observer/filing/0001193125-26-028186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526028186/0001193125-26-028186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526028186/dftx-20260128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:30:50.338390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}